SEC Form 4 · accession 0001179110-16-028912
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bradford J Shafer
Officer — EVP, Gen. Counsel, Secretary
Period of report
Aug 18, 2016
Accepted (ET)
Aug 22, 2016 · 7:08 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Aug 18, 2016 | S | 7,174 | $28.55 | D | 241,686 | D | |
| Ordinary SharesF2 | Aug 19, 2016 | S | 4,870 | $28.14 | D | 236,816 | D | |
| Ordinary Shares | Aug 20, 2016 | F | 4,008 | $27.89 | D | 232,808 | D | |
| Ordinary SharesF3 | Aug 22, 2016 | S | 37,078 | $27.16 | D | 195,730 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices from $28.50 to $28.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or any security holder of the issuer, full information regarding the number of shares and prices at which the transactions set forth in footnotes (1) through (3) to this Form 4 were effected.
- F2This transaction was executed in multiple trades at prices from $28.00 to $28.40. The price reported above reflects the weighted average sale price.
- F3This transaction was executed in multiple trades at prices from $27.00 to $27.76. The price reported above reflects the weighted average sale price.